Protagonist Therapeutics PTGX Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Protagonist Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DeferredIncomeCurrent.
The official record: Protagonist Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Protagonist Therapeutics's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Protagonist Therapeutics's deferred revenue?
- Protagonist Therapeutics (PTGX) reported deferred revenue of $6.28M in Q1 2026.
- How has Protagonist Therapeutics's deferred revenue changed year-over-year?
- Protagonist Therapeutics's deferred revenue decreased by 23.2% year-over-year, from $8.18M to $6.28M.
- What is the long-term trend for Protagonist Therapeutics's deferred revenue?
- Over 5 years (2020 to 2025), Protagonist Therapeutics's deferred revenue has grown at a -8.0% compound annual growth rate (CAGR), from $14.48M to $9.55M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.